Find a clinical trial
Managed Access Program Allowing Access to Olorofim
This is a managed access programme for patients meeting the entry criteria eithe de novo or completing a clinical trial
- Trial name
- NCT07895264
- Testing
- Anti Fungal Drug, Olorofim is a novel antifungal drug
- Sponsor
- F2G Ltd
TNBC, TNBC - Triple-Negative Breast Cancer
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
This Expanded Access Program provides investigational access to leronlimab (PRO 140) for patients with advanced or metastatic triple-negative breast cancer (TNBC) who lack satisfactory treatment options and are unable to…
- Conditions
- TNBC, TNBC - Triple-Negative Breast Cancer, TNBC, Triple Negative Breast Cancer
- Trial name
- NCT07536815
- Testing
- leronlimab (PRO 140)
- Where
- United States
- Sponsor
- CytoDyn, Inc.
Autoimmune Pulmonary Alveolar Proteinosis
Molgramostim Nebulizer Solution Expanded Access Program Protocol
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disorder in which a material called surfactant builds up in the lungs and makes it hard to breathe.
- Trial name
- NCT06546098
- Testing
- Molgramostim nebulizer solution
- Where
- 12 sites in United States
- Sponsor
- Savara Inc.
Fibrodysplasia Ossificans Progressiva (FOP)
An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)
The objective of this Expanded Access Program (EAP) is to provide garetosmab to adult patients with Fibrodysplasia Ossificans Progressiva (FOP), including patients who have completed the double-blind treatment period of the…
- Trial name
- NCT07301450
- Testing
- Garetosmab
- Sponsor
- Regeneron Pharmaceuticals
Brain Injury
Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patients With Traumatic or Nontraumatic Brain Injury
This expanded access protocol is part of IND 031942 to evaluate efficacy and safety of multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of nontraumatic or traumatic brain injury for up to 8 patients…
- Trial name
- NCT07164482
- Testing
- HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer
The primary objective of this expanded access program (EAP) is to provide early access to giredestrant for participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) early breast…
- Trial name
- NCT07643831
- Testing
- Giredestrant
- Where
- 9 sites in United States
- Sponsor
- Genentech, Inc.
Still's Disease, Including SJIA and AOSD, With MAS or ILD Complications
Managed Access Programs for MAS825, Arumakimig
The purpose of this registration is to list Managed Access Programs (MAPs) related to MAS825, arumakimig
- Trial name
- NCT07889310
- Testing
- Arumakimig
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease, ASCVD
Managed Access Programs for TQJ230, Pelacarsen
The purpose of this registration is to list Managed Access Programs (MAPs) related to TQJ230, pelacarsen
- Trial name
- NCT07000695
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
Epilepsies, Myoclonic, Drug Resistant Epilepsy
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.
- Trial name
- NCT04457687
- Testing
- Lorcaserin
- Where
- 22 sites in United States, Canada
- Sponsor
- Eisai Inc.
Breast Cancer
Managed Access Programs for LEE011, Ribociclib
The purpose of this registration is to list Managed Access Programs (MAPs) related to LEE011, Ribociclib
- Trial name
- NCT05038631
- Testing
- Ribociclib
- Sponsor
- Novartis Pharmaceuticals
Mitochondrial Diseases, Barth Syndrome
An Intermediate Size Expanded Access Protocol of Elamipretide
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor to learn more about this program.
- Trial name
- NCT04689360
- Testing
- elamipretide
- Sponsor
- Stealth BioTherapeutics Inc.
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease
An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.
- Trial name
- NCT06939647
- Testing
- Treprostinil Palmitil
- Sponsor
- Insmed Incorporated
Prosthetic-joint Infection
Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty
The objective of the protocol is to provide access to the VT-X7 (Vancomycin, Tobramycin Exchanged in 7 Days) system for subjects with periprosthetic joint infection (PJI) of the hip or knee who lack therapeutic treatment…
- Trial name
- APEX-EAP (NCT06383611)
- Testing
- VT-X7 Treatment System
- Where
- 14 sites in United States
- Sponsor
- Osteal Therapeutics, Inc.
Tourettes Disorder, Tourette Disorder
Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder
The goal of this expanded access study is to learn about the long-term effects of Ecopipam in participants with Tourette's Disorder (TD).
- Trial name
- EBS-101-TD-392 (NCT07093541)
- Testing
- ecopipam HCl ~2mg/kg/day
- Where
- 26 sites in United States
- Sponsor
- Emalex Biosciences Inc.
Meniere's Disease, Meniere Disease
Expanded Access Protocol for SPI-1005
The purpose of this protocol is to facilitate expanded access ("compassionate use") of SPI-1005 to Meniere's disease (MD) or sudden sensorineural hearing loss (SSNHL) patients who cannot gain access through ongoing clinical…
- Conditions
- Meniere's Disease, Meniere Disease, Meniere´s Disease, Meniere's Disease Aggravated
- Trial name
- NCT07873281
- Testing
- Ebselen
- Sponsor
- Sound Pharmaceuticals, Incorporated
Peripheral T-cell Lymphomas, Adult T-cell Leukemia/Lymphoma
Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)
Valemetostat tosylate demonstrates antitumour activity in patients with peripheral T-cell lymphomas (PTCL) with a manageable safety profile.
- Conditions
- Peripheral T-cell Lymphomas, Adult T-cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, Refractory Nodal T-follicular Helper Lymphoma
- Trial name
- NCT07862465
- Testing
- Valemetostat tosylate
- Sponsor
- Daiichi Sankyo
Hereditary Angioedema (HAE)
Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 Study
This protocol for post study access allows pediatric participants (2-11 years old at the time of consent) with HAE who have completed study CSL312_3003 (NCT05819775) to continue treatment with CSL312 for routine prevention of HAE…
- Trial name
- NCT07159464
- Testing
- CSL312
- Sponsor
- CSL Behring
Non-Small Cell Lung Cancer
An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this expanded access program (EAP) is to provide early access to divarasib to participants with KRAS G12C-positive (KRAS G12C+) advanced or metastatic non-small cell lung cancer (NSCLC), prior to divarasib becoming…
- Trial name
- NCT07783009
- Testing
- Divarasib
- Where
- United States
- Sponsor
- Genentech, Inc.
Ebola Virus Disease
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
- Trial name
- NCT03576690
- Testing
- REGN3470-3471-3479
- Sponsor
- Regeneron Pharmaceuticals
Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL)
A Compassionate Use (CU) Program of Odronextamab
Provide compassionate use of odronextamab
- Conditions
- Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Non-Hodgkin Lymphoma (NHL), High-Grade B-Cell Lymphoma (HGBCL)
- Trial name
- NCT05619367
- Testing
- Odronextamab
- Sponsor
- Regeneron Pharmaceuticals